ThorstenGnad

Novo Nordisk buys CBMR spinout Embark Biotech, in a deal worth up to €456 million, to acquire their novel approach for treating #obesity and type 2 diabetes! 🚀 “It is a dream come true to have this opportunity to work with Novo Nordisk and strive to transform our discovery into powerful new therapies that could improve the lives of people living with obesity and type 2 diabetes,” says Associate Professor Zach Gerhart-Hines. At CBMR, Associate Professor Zach Gerhart-Hines, together with his former postdoc, Jakob Bondo Hansen and Professor @Thue_Schwartz discovered that by stimulating a single, previously overlooked receptor with carefully designed, long-acting molecules, it was possible to achieve a similar appetite-suppressing outcome as GLP-1 agonists such as @novonordisk's #Wegovy. But in addition, these novel molecules also increased the capacity to burn energy and, importantly, directly improved insulin sensitivity. “I am incredibly proud of being part of this amazing story. A true basic scientific discovery has led to the development of a totally novel therapeutic approach that targets the Holy Grail in diabetes and obesity treatment – energy expenditure and insulin sensitivity. All starting with the establishment of CBMR and the recruitment of Zach and his team 10 years ago,” says Thue W. Schwartz, Scientific Godfather of Embark. Read the full story on the CBMR website 👇 🔗cbmr.ku.dk/news/2023/novo-no…